Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

66.06
-2.0800-3.05%
Pre-market: 66.300.2400+0.36%09:27 EDT
Volume:2.93M
Turnover:195.72M
Market Cap:5.71B
PE:-14.63
High:69.57
Open:68.55
Low:65.34
Close:68.14
Loading ...

CRISPR Therapeutics (CRSP) Surges 71% Last Quarter With Inclusion In Russell Indices

Simply Wall St.
·
Yesterday

Crispr Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
23 Jul

CRISPR Therapeutics Pick of the Week at Smart Insider Following Simeon George's Stock Purchase

MT Newswires Live
·
22 Jul

Crispr Therapeutics price target lowered to $78 from $79 at BofA

TIPRANKS
·
22 Jul

AI Biotech Stocks Shined. Recursion Soared 10%; Absci Up 7%; Crispr Up 6%; Beam And Ginkgo Up 3%

Tiger Newspress
·
21 Jul

3 Monster Stocks in the Making to Buy Right Now

Motley Fool
·
21 Jul

Crispr Therapeutics AG Stock Soars Amid Insider Confidence

TIPRANKS
·
19 Jul

CRISPR Therapeutics (CRSP) Surges after Director Buys over $51M Worth of Shares

TIPRANKS
·
19 Jul

Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG!

TIPRANKS
·
18 Jul

CRISPR Therapeutics AG Director George Simeon Reports Acquisition of Common Shares

Reuters
·
18 Jul

Crispr Therapeutics AG Stock Soars Amid Strategic Moves

TIPRANKS
·
12 Jul

CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results

Simply Wall St.
·
10 Jul

Cathie Wood’s ARK Investment buys 103K shares of Crispr Therapeutics today

TIPRANKS
·
09 Jul

Crispr Therapeutics Price Target Maintained With a $81.00/Share by Needham

Dow Jones
·
08 Jul

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Jul

Crispr Therapeutics AG Stock Soars Amid Clinical Advances

TIPRANKS
·
05 Jul

2 Beaten-Down Stocks With Massive Upside Potential

Motley Fool
·
03 Jul

2 Growth Stocks to Buy Hand Over Fist in July

Motley Fool
·
02 Jul

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and Pharvaris (PHVS)

TIPRANKS
·
30 Jun

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

Motley Fool
·
28 Jun